As in the preclinical exploration, the model suggests that first IL6 peak is primarily driven by production in the PB and the contribution of tissue cytokines to serum cytokine levels is minimal, whereas the subsequent peaks primarily reflect the contribution of tissue/tumor IL6 after PB but not tumor B-cells are depleted. This evidence concerns the gene IL6 and neoplasm.